Published Paper Details:

Eucalyptus (Eucalyptus spp.), an evergreen tall tree native to Australia and Tasmania, has been used since ancient times by the aboriginal population for several purposes. In particular, the species E. globulus is widely used in the pulp industry, as well as for the production of eucalyptus oil extracted on a commercial scale in many countries as raw materials in perfumery, cosmetics, food, beverages, aromatherapy and phytotherapy. The 1,8-cineole (eucalyptol), the principal and the most important constituents extracted from eucalyptus leaves, demonstrated an antimicrobial and anti- inflammatory activities. Despite the fact that the healthy effects of eucalyptus have been well established by research, further studies are necessary to investigate other prime effects of the plant and its possible implication in the treatment of a greater number of pathological conditions. The interest in the use of Eucalyptus genus members, in parallel with preclinical studies has been steadily growing over the last few decades in the field of pharmaceuticals, agriculture, cosmetics, food, etc. Eucalyptol (1,8-cineole or cineole), the main terpenoid constituent in Eucalyptus species, has been studied in both preclinical and clinical settings for its various pharmacologic activities. Investigations into the pharmacological activities of the genus Eucalyptus revealed that it manifests astounding potential in the treatment and management of respiratory disorders, COVID-19, pain, oral health, infectious diseases, cancer, etc.